113 related articles for article (PubMed ID: 6266642)
1. Combination chemotherapy with and without the methanol-extracted residue of bacillus Calmette-Guerin (MER) in extensive non-small-cell lung cancer: a prospective randomized study for the Piedmont Oncology Association.
Richards F; Howard V; Shore A; Muss HB; White DR; Jackson DV; Cooper MR; Bearden J; Stuart JJ; Sartiano G; Rhyne AL; Spurr CL
Cancer; 1981 Jun; 47(12):2827-32. PubMed ID: 6266642
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy-radiotherapy with and without the methanol-extraction residue of Bacillus Calmette-Guerin (MER) in small cell carcinoma of the lung: a prospective randomized trial of the Piedmont Oncology Association.
Jackson DV; Paschal BR; Ferree C; Richards F; Muss HB; Cooper MR; White DR; Stuart JJ; Spurr CL; Wells B; Sartiano G; McFarland J; McCulloch J
Cancer; 1982 Jul; 50(1):48-52. PubMed ID: 6282434
[TBL] [Abstract][Full Text] [Related]
3. Combined-modality treatment of inoperable lung cancer (i.v. immunotherapy, chemotherapy, and radiotherapy).
Robinson E; Haim N; Segal R; Veseley Z; Mekori T
Cancer Treat Rep; 1985 Mar; 69(3):251-8. PubMed ID: 2983892
[TBL] [Abstract][Full Text] [Related]
4. Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: a Phase III cancer and Leukemia Group B Study.
Maurer LH; Pajak T; Eaton W; Comis R; Chahinian P; Faulkner C; Silberfarb PM; Henderson E; Rege VB; Baldwin PE
J Clin Oncol; 1985 Jul; 3(7):969-76. PubMed ID: 2991478
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy versus chemoimmunotherapy with levamisole or Corynebacterium parvum in advanced lung cancer.
Chahinian AP; Goldberg J; Holland JF; Reisman A; Jaffrey IS; Mandel EM
Cancer Treat Rep; 1982 Jun; 66(6):1291-7. PubMed ID: 6282455
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy vs. chemoimmunotherapy with methanol extraction residue of Bacillus Calmette-Guerin (MER) in advanced breast cancer: a randomized trial by the Piedmont Oncology Association.
Muss HB; Richards F; Cooper MR; White DR; Jackson DV; Stuart JJ; Howard V; Shore A; Rhyne AL; Spurr CL
Cancer; 1981 May; 47(9):2295-301. PubMed ID: 7226124
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy versus chemoimmunotherapy for small-cell undifferentiated carcinoma of the lung.
Aisner J; Wiernik PH
Cancer; 1980 Dec; 46(12):2543-9. PubMed ID: 6256048
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy of extensive large cell and adenocarcinoma of the lung: a randomized trial in 210 patients.
Vincent RG; Mehta CR; Tucker RD; Mountain CF; Cohen M; Wilson HE; Vogel C
Cancer; 1980 Jul; 46(2):256-60. PubMed ID: 6992978
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.
Aisner J; Weinberg V; Perloff M; Weiss R; Perry M; Korzun A; Ginsberg S; Holland JF
J Clin Oncol; 1987 Oct; 5(10):1523-33. PubMed ID: 3655855
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy plus methanol extracted residue of bacillus Calmette-Guérin or Corynebacterium parvum in stage III lung cancer.
Bjornsson S; Takita H; Kuberka N; Preisler H; Catane H; Higby D; Henderson E
Cancer Treat Rep; 1978 Apr; 62(4):505-10. PubMed ID: 350388
[TBL] [Abstract][Full Text] [Related]
11. MACC (methotrexate, adriamycin, cyclophosphamide and CCNU) in advanced lung cancer.
Chahinian AP; Mandel EM; Holland JF; Jaffrey IS; Teirstein AS
Cancer; 1979 May; 43(5):1590-7. PubMed ID: 221093
[No Abstract] [Full Text] [Related]
12. MACC chemotherapy for adenocarcinoma and epidermoid carcinoma of the lung: low response rate in a Cooperative Group Study. Eastern Cooperative Oncology Group.
Vogl SE; Mehta CR; Cohen MH
Cancer; 1979 Sep; 44(3):864-8. PubMed ID: 476598
[TBL] [Abstract][Full Text] [Related]
13. The treatment of lung cancer.
Zubrod CG; Selawry O
Adv Intern Med; 1978; 23():451-67. PubMed ID: 204171
[No Abstract] [Full Text] [Related]
14. Four-drug combination chemotherapy in advanced lung cancer: methotrexate, doxorubicin, cyclophosphamide and CCNU.
Milstein D; Robinson E
Cancer; 1981 Dec; 48(11):2358-63. PubMed ID: 7028245
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy, radiotherapy, and BCG immunotherapy in extensive (metastatic) small cell carcinoma of the lung. A Southwest Oncology Group study.
McCracken JD; Heilbrun L; White J; Reed R; Samson M; Saiers JH; Stephens R; Stuckey WJ; Bickers J; Livingston R
Cancer; 1980 Dec; 46(11):2335-40. PubMed ID: 6254629
[TBL] [Abstract][Full Text] [Related]
16. Single-agent and combination chemotherapy for extensive non-small cell carcinomas of the lung.
Davis S; Pandya MR; Rambotti P
Cancer Treat Rep; 1980; 64(4-5):685-8. PubMed ID: 6253067
[TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced breast cancer with cyclophosphamide, 5-fluorouracil, and prednisone with and without methanol-extracted residue of BCG.
Britell JC; Ahmann DL; Bisel HF; Frytak S; Ingle JN; Rubin J; O'Fallon JR
Cancer Clin Trials; 1979; 2(4):345-50. PubMed ID: 394870
[TBL] [Abstract][Full Text] [Related]
18. Chemo-immunotherapy for unresectable bronchogenic carcinoma.
Sarna GP; Lowitz BB; Haskell CM; Dorey FJ; Cline MJ
Cancer Treat Rep; 1978 May; 62(5):681-7. PubMed ID: 350397
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations.
Aisner J; Whitacre M; Van Echo DA; Wiernik PH
Cancer Treat Rep; 1982 Feb; 66(2):221-30. PubMed ID: 6275987
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy for inoperable, non-small cell bronchogenic carcinoma: EST 2575, generation II.
Ruckdeschel JC; Mehta CR; Salazar OM; Cohen M; Vogl S; Koons LS; Lerner H
Cancer Treat Rep; 1981; 65(11-12):965-72. PubMed ID: 7028258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
